These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 16036037

  • 1. Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure.
    Lehtonen L.
    Curr Heart Fail Rep; 2004 Sep; 1(3):136-44. PubMed ID: 16036037
    [Abstract] [Full Text] [Related]

  • 2. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L.
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [Abstract] [Full Text] [Related]

  • 3. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L, Põder P.
    Ann Med; 2007 May; 39(1):2-17. PubMed ID: 17364447
    [Abstract] [Full Text] [Related]

  • 4. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M, Lehtonen L.
    Curr Pharm Des; 2005 May; 11(4):435-55. PubMed ID: 15725064
    [Abstract] [Full Text] [Related]

  • 5. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y.
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [Abstract] [Full Text] [Related]

  • 6. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties.
    Lehtonen LA.
    Expert Opin Investig Drugs; 2001 May; 10(5):955-70. PubMed ID: 11322869
    [Abstract] [Full Text] [Related]

  • 7. Levosimendan: dual mechanisms for acute heart failure...and beyond?
    Ng TM, Akhter MW.
    Minerva Cardioangiol; 2005 Dec; 53(6):565-84. PubMed ID: 16333239
    [Abstract] [Full Text] [Related]

  • 8. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F.
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Considerations on the efficacy and safety of levosimendan in ischemic heart failure.
    Nieminen MS, Sandell EP.
    Ital Heart J; 2003 May; 4 Suppl 2():39S-44S. PubMed ID: 14635369
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Levosimendan in cardiology and intensive care medicine].
    Delle Karth G, Heinz G.
    Wien Klin Wochenschr; 2004 Jan 31; 116(1-2):6-14. PubMed ID: 15030117
    [Abstract] [Full Text] [Related]

  • 19. Levosimendan, a new calcium-sensitizing inotrope for heart failure.
    Ng TM.
    Pharmacotherapy; 2004 Oct 31; 24(10):1366-84. PubMed ID: 15628834
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan.
    Papp Z, Csapó K, Pollesello P, Haikala H, Edes I.
    Cardiovasc Drug Rev; 2005 Oct 31; 23(1):71-98. PubMed ID: 15867949
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.